This Plain Language Summary of Publication article (PLSP) from Future Science OA tested how well alectinib worked compared to chemotherapy in patients with ALK-positive non-small cell lung cancer (NSCLC) after surgery. ALK-positive NSCLC occurs when changes in the ALK gene create overactive proteins that promote cancer growth. Alectinib is a tyrosine kinase inhibitor that blocks these overactive ALK proteins, helping to slow cancer growth.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer’ and was published in The New England Journal of Medicine.

Visit NEJM using the link to read the original article.